Consensus-driven target product profiles for curative sickle cell disease gene therapies.

Autor:	Bukini D; Sickle Cell Disease Program, Muhimbili University of Health and Allied Sciences, Dar es Salaam 65001, Tanzania., Makani J; Sickle Cell Disease Program, Muhimbili University of Health and Allied Sciences, Dar es Salaam 65001, Tanzania.; SickleInAfrica, Clinical Coordinating Center, Muhimbili University of Health and Allied Sciences, Dar es Salaam 65001, Tanzania.; Imperial College London, SW7 2AZ London, UK., McCune J; HIV Frontiers, Global Health Accelerator, Bill & Melinda Gates Foundation, Seattle, WA 98109, USA., Lee D; HIV Frontiers, Global Health Accelerator, Bill & Melinda Gates Foundation, Seattle, WA 98109, USA., Bansbach C; Chinacat Enterprises LLC, Gig Harbor, WA 98332, USA., De Vita S; Translational Clinical Oncology, Biomedical Research, Novartis, Cambridge, MA 02139, USA., Kemps D; HIV Cure Africa Acceleration Partnership, Sommartel, NW1 8DS London, UK., Amin E; Global Health, Biomedical Research, Novartis, Emeryville, CA 94608, USA., Spector J; Global Health, Biomedical Research, Novartis, Cambridge, MA 02139, USA., Tisdale J; Cellular and Molecular Therapeutics Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20814, USA.
Jazyk:	angličtina
Zdroj:	Molecular therapy. Methods & clinical development [Mol Ther Methods Clin Dev] 2024 Jun 22; Vol. 32 (3), pp. 101287. Date of Electronic Publication: 2024 Jun 22 (Print Publication: 2024).
DOI:	10.1016/j.omtm.2024.101287
Abstrakt:	Therapeutic innovation to address sickle cell disease (SCD) is at a historical apex, characterized by a drug discovery, development, and commercialization landscape that includes potentially curative gene therapies. Given the wide geographic distribution of SCD, with a major presence in Africa, it is imperative that new medicines are designed to meet the specific needs of persons with SCD everywhere. Target product profiles (TPPs) detail the desired attributes of new medicines and serve as a guide for drug developers. To support research efforts for curative treatments for SCD, we mobilized a large multi-disciplinary expert group to generate consensus-driven TPPs for ex vivo and in vivo SCD gene therapies, utilizing a modified Delphi methodology supplemented with virtual workshops. The main findings are TPPs that describe 20 minimal and optimal criteria for novel gene therapy products in categories of scope (3 criteria), performance/safety (11 criteria), manufacturing (4 criteria), and administration (2 criteria). TPPs for ex vivo and in vivo products differed in some performance/safety criteria and all criteria pertaining to manufacturing and administration. These outputs will ideally support development of durable treatments that are safe, efficacious, and practical for persons with SCD in global settings. Competing Interests: S.D.V., E.A., and J.S. are employees of Novartis Biomedical Research. (© 2024 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu